Drugs / Adavosertib
last change Jul 2026 re-read 2 minutes ago

Adavosertib

also known as AZD1775 · MK1775 · ADAVOSERTIB (MK-1775)

Small molecule targets WEE1 via inhibition

Developed for
cancer · small cell lung carcinoma · acute myeloid leukemia · cervical carcinoma · fallopian tube carcinoma · glioblastoma · head and neck squamous cell carcinoma · hypopharynx squamous cell carcinoma
+67 more · metastatic malignant neoplasm · myelodysplastic syndrome · ovarian cancer · ovarian carcinoma · pancreatic adenocarcinoma · plasma cell myeloma · primary peritoneal carcinoma · refractory malignant neoplasm · uterine corpus cancer · adult lymphoma · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · cervical cancer · childhood acute myeloid leukemia · childhood malignant neoplasm · childhood supratentorial embryonal tumor with multilayered rosettes, C19MC-altered · clear cell renal carcinoma · colorectal cancer · endometrial serous adenocarcinoma · endometrioid adenocarcinoma · esophageal adenocarcinoma · esophageal squamous cell carcinoma · fallopian tube serous adenocarcinoma · ganglioneuroblastoma · gastric adenocarcinoma · gastric cardia adenocarcinoma · gastroesophageal junction adenocarcinoma · high grade malignant neoplasm · infiltrating bladder urothelial carcinoma · larynx cancer · larynx verrucous carcinoma · lung cancer · malignant epithelial tumor of ovary · malignant pancreatic neoplasm · medulloblastoma · metastatic neoplasm · metastatic squamous cell carcinoma · myelodysplastic syndrome associated with isolated del(5q) · myelofibrosis · nasal cavity and paranasal sinus squamous cell carcinoma · neoplasm · neoplastic disease or syndrome · neuroblastoma · non-small cell lung carcinoma · oral cavity squamous cell carcinoma · oropharynx squamous cell carcinoma · ovarian Brenner tumor · ovarian carcinosarcoma · ovarian clear cell cystadenocarcinoma · ovarian endometrioid adenocarcinoma · ovarian mucinous cystadenocarcinoma · ovarian seromucinous carcinoma · ovarian serous adenocarcinoma · ovarian serous cystadenocarcinoma · ovarian serous surface papillary adenocarcinoma · pineoblastoma · primary peritoneal serous adenocarcinoma · prostate cancer · rhabdoid tumor · rhabdomyosarcoma · therapy related acute myeloid leukemia and myelodysplastic syndrome · tongue carcinoma · triple-negative breast carcinoma · undifferentiated ovarian carcinoma · uterine cancer · vaginal carcinoma · verrucous carcinoma of oral cavity · diffuse intrinsic pontine glioma
Investigated by
AstraZeneca · National Cancer Institute (NCI) · Merck Sharp & Dohme LLC · Parexel · Dana-Farber Cancer Institute · Quintiles, Inc.
+29 more · Samsung Medical Center · M.D. Anderson Cancer Center · NYU Langone Health · American Society of Clinical Oncology · BC Cancer Foundation · Barbara Ann Karmanos Cancer Institute · Canadian Cancer Clinical Trials Network · Canadian Cancer Trials Group · Cancer Research UK · Fight Kids Cancer · Fondation ARC · Gustave Roussy, Cancer Campus, Grand Paris · H. Lee Moffitt Cancer Center and Research Institute · James Cleary, MD, PhD · Joseph Paul Eder · Lustgarten Foundation · Mayo Clinic · National Cancer Institute, France · St. Joseph's Hospital and Medical Center, Phoenix · Stand Up To Cancer · The Ben & Catherine Ivy Foundation · The Cleveland Clinic · The Netherlands Cancer Institute · Translational Genomics Research Institute · UNC Lineberger Comprehensive Cancer Center · University of Birmingham · University of Michigan Rogel Cancer Center · University of Washington · Vanderbilt-Ingram Cancer Center

Trials 60 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT02659241 Feb 2016 → Dec 2026 expected fallopian tube serous adenocarcinoma, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma M.D. Anderson Cancer Center Active not recruiting No outcome recorded
Phase 0 NCT02207010 Jul 2014 → Dec 2015 glioblastoma St. Joseph's Hospital and Medical Center, Phoenix Completed No outcome recorded
Phase 127 trials
Phase 1 NCT05008913 Oct → Nov 2021 cancer AstraZeneca Terminated No outcome recorded
Phase 1 NCT04949425 Sep 2021 → Apr 2022 cancer AstraZeneca Terminated No outcome recorded
Phase 1 NCT04959266 Jun 2021 → Jun 2022 cancer AstraZeneca Terminated No outcome recorded
Phase 1 NCT04460937 Apr 2021 → Mar 2024 overdue esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric cardia adenocarcinoma, gastroesophageal junction adenocarcinoma +2 National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1 NCT04197713 Jun 2020 → Feb 2023 overdue metastatic malignant neoplasm National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1 NCT04462952 Jun 2020 → Sep 2021 neoplasm AstraZeneca Completed No outcome recorded
Phase 1 NCT03345784 May 2018 → May 2022 cervical carcinoma, endometrioid adenocarcinoma, uterine corpus cancer, vaginal carcinoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT03333824 Dec 2017 → Jan 2019 cancer AstraZeneca Completed No outcome recorded
Phase 1 NCT03313557 Oct 2017 → May 2019 cancer AstraZeneca Completed No outcome recorded
Phase 1 NCT03315091 Sep 2017 → Apr 2018 cancer AstraZeneca Completed No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT02813135 Aug 2016 → Feb 2031 expected childhood malignant neoplasm Gustave Roussy, Cancer Campus, Grand Paris Recruiting No outcome recorded
Phase 1/2 NCT02194829 Aug 2014 → Jun 2021 pancreatic adenocarcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT02095132 Mar 2014 → Dec 2020 childhood supratentorial embryonal tumor with multilayered rosettes, C19MC-altered, ganglioneuroblastoma, medulloblastoma, neuroblastoma +3 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT02037230 Jan 2014 → Aug 2018 pancreatic adenocarcinoma University of Michigan Rogel Cancer Center Completed No outcome recorded
Phase 1/2 NCT01076400 May 2010 → Jun 2011 cervical cancer Merck Sharp & Dohme LLC Terminated No outcome recorded
Phase 226 trials
Phase 2 NCT05212025 Jun 2022 → Jun 2023 malignant pancreatic neoplasm James Cleary, MD, PhD Withdrawn No outcome recorded
Phase 2 NCT04590248 Nov 2020 → May 2022 endometrial serous adenocarcinoma AstraZeneca Completed No outcome recorded
Phase 2 NCT03718143 May → Sep 2019 acute myeloid leukemia, myelodysplastic syndrome, myelofibrosis NYU Langone Health Terminated No outcome recorded
Phase 2 NCT03284385 Jan 2019 → Mar 2026 overdue clear cell renal carcinoma, metastatic malignant neoplasm National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 2 NCT03253679 Jan 2019 → Oct 2022 high grade malignant neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT03579316 Dec 2018 → Dec 2026 expected fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma M.D. Anderson Cancer Center Active not recruiting No outcome recorded
Phase 2 NCT03668340 Oct 2018 → Jul 2026 overdue uterine cancer Dana-Farber Cancer Institute Active not recruiting No outcome recorded
Phase 2 NCT03385655 Aug 2018 → Oct 2024 overdue prostate cancer Canadian Cancer Trials Group Active not recruiting No outcome recorded
Phase 2 NCT02666950 May 2017 → Sep 2018 acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome associated with isolated del(5q) Mayo Clinic Completed No outcome recorded
Phase 2 NCT04439227 Mar 2017 → Dec 2026 expected adult lymphoma, plasma cell myeloma, refractory malignant neoplasm National Cancer Institute (NCI) Active not recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03330847 Comparator Mar 2018 → Nov 2020 overdue triple-negative breast carcinoma AstraZeneca Active not recruiting No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 66 sources stand behind the page.

FieldValueCited text
Known as adavosertib Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.” PMID 37368100 Jun 2023
31

“Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.” PMID 33705205 Mar 2021

Adavosertib (AZD1775) is a first-in-class, selective, small-molecule inhibitor of Wee1.” PMID 37278879 Jun 2023

NCT05008913

NCT00648648

NCT01849146

NCT01076400

NCT01827384

NCT04439227

NCT04460937

NCT02465060

NCT02659241

NCT03579316

NCT04590248

NCT04959266

NCT02813135

NCT04197713

NCT02095132

NCT03330847

NCT04949425

NCT02101775

NCT01357161

NCT02272790

NCT04462952

NCT01922076

NCT03345784

NCT03253679

NCT05212025

NCT03385655

NCT02381548

NCT03284385

NCT01047007

Known as ADAVOSERTIB (MK-1775) ChEMBL registry synonym — accepted as the source's own label CHEMBL1976040
Known as AZD1775 “In contrast to recent preclinical data, our phase 0 study of AZD 1775 in recurrent glioblastoma indicates good human brain tumor penetration, provides the first evidence of...” PMID 29798906 May 2018
32

AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.” NCT02511795

“Adavosertib (AZD1775) is a first-in-class, selective, small-molecule inhibitor of Wee1.” PMID 37278879 Jun 2023

“MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.” NCT01748825

“adavosertib \[AZD1775\]” NCT03330847

“Adavosertib (AZD1775)” NCT04462952

NCT02087176

NCT03028766

NCT02341456

NCT02666950

NCT03012477

NCT02194829

NCT02576444

NCT02196168

NCT02610075

NCT03315091

NCT02513563

NCT02937818

NCT02791919

NCT02546661

NCT02087241

NCT02593019

NCT02617277

NCT02906059

NCT02207010

NCT02585973

NCT02448329

NCT03313557

NCT02508246

NCT03333824

NCT03718143

NCT03668340

NCT02688907

Known as MK1775 “AZD1775 (previously known as MK-1775 in earlier studies) is an inhibitor of Wee1, a protein tyrosine kinase.” NCT02593019
5

“AZD1775 (previously known as MK-1775 in earlier studies) is an inhibitor of Wee1, a protein tyrosine kinase.” NCT02688907

MK1775NCT02095132

NCT02037230

NCT01164995

NCT01748825

Action Inhibit inhibitor of Wee1-kinase” NCT01748825
Modality Small molecule “BACKGROUND: Adavosertib is a highly selective, small molecule Wee1 inhibitor” PMID 41212474 Nov 2025
Route Oral “adavosertib administered as an oral formulation” NCT00648648
Target WEE1 “inhibitor of Wee1-kinase” NCT01748825